# A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Source: https://onco.cc/trials/nct06232096/  
OnCo record `nct06232096` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MBS314 Injection in multiple myeloma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.

## Summary

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. is a phase 1/2 interventional study registered as NCT06232096 by Beijing Mabworks Biotech Co., Ltd., with 154 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-02. Interventions recorded: MBS314 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06232096
- Phase: 1/2
- Setting: A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 Injection in Patients With Relapsed/Refractory Multiple Myeloma.
- Sponsor: Beijing Mabworks Biotech Co., Ltd.
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT06232096: https://clinicaltrials.gov/study/NCT06232096

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Beijing Mabworks Biotech](https://onco.cc/companies/beijing-mabworks-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct06232096.json